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Background: The role of transmitted drug resistance (TDR) in predicting outcomes of initial
antiretroviral therapy including PI or INSTI has not been fully explored.
Methods: From the ARCA database we selected adult naïve HIV-1 infected patients starting first-line
3-drugs therapy including INSTI or PI, from 1/2008 to 6/2016, with baseline resistance genotype
and at least 1 HIV-1 RNA during follow up. TDR was defined as the detection of at least one mutation
among those included in the WHO-recommended SDRM list (Bennett 2009). The primary endopoints
were: virological failure (VF, defined as an HIV-RNA, VL, > 200 copies/ml after week 24) and
treatment failure (TF, defined as VF or treatment change for any reason). Survival analysis was used
to investigate predictors of TF and VF.
Results: 1147 pts were analyzed: 1031 (89.9%) treated with PI and 116 (10.1%) with INSTI.
Baseline characteristics are shown in table. In the PI-group baseline VL was higher while CD4+ cells
count was lower than in INSTI. Overall TDR were 4.7% for NRTI, 4.4% NNRTI, 1.5% PI without
significant differences between groups.
During a median observation time of 57 wks (IQR 26-107) TF occurred in 771 treatments in PI-
group, with an estimated probability at 48 wks of 36% (CI 34.5-37.5) and in 46 in INSTI-group with
an estimated probability at 48 wks of 31% (26.2-35.8); during a median observation time of 55 wks
(26-107) VF occurred in 161 treatments in PI-group, with an estimated probability at 48 wks of 12%
(10.8-13.1) and in 11 in INSTI-group with an estimated probability at 48 wks of 12% (8.5-15.5).
After adjusting for gender, nationality, TDF/FTC use and viral subtype, independent predictor of VF
was AZT/3TC use (vs other backbones HR 3.8, CI 95% 2.2-6.3, p<0.001); adjusting for nationality
and viral subtype, independent predictors of TF were geographic area (Southern vs Northern Italy,
HR 0.8, 0.6-0.9, p=0.04), baseline VL (+ 1 log10 HR 1.1, 1.0-1.2, p=0.03) and AZT/3TC (versus
other backbones HR 2.1, 1.5-2.8, p=<0.001). Third drug class was not associated with VF or TF. In
the INSTI-group, but not in the PI-group, the presence of any NRTI TDR was predictor of VF (HR 7.1,
1.8-28.2, p=0.005) after adjusting for nadir CD4 cells count and TF (HR 2.7, 1.1-7.0, p=0.03).
Among patients in the INSTI-group with VF, 3 presented NRTI TDR (2 M41L and 1 M184V). In the
PI-group, adjusting for gender, nationality, geographic area, viral subtype, TDF/FTC use, baseline
and nadir CD4 cells count, independent predictor of VF was AZT/3TC use (HR 3.4, 1.8-6.2,
p<0.001); adjusting for nationality and viral subtype, independent predictor of TF was AZT/3TC use
(vs other backbones HR 2.3, 1.7-3.1, p<0.001).
Conclusions: PI and INSTI based first-line regimens show high efficacy in the real practice; despite
the low incidence of TDR, our data support the need of pre-treatment genotyping to optimize therapy
in patients starting INSTI-therapy. Further studies are required to confirm our suggestions.
Table. Comparison of baseline characteristics between PI-group and INSTI-group 
*Potential	differences	between	the	two	groups	were	evaluated	by	Chi-Squared	test	for	categorical	variables	and	by	t-
Student	test	for	continuous	variables.	
Characteristics 
Overall PI-group INSTI-group P-value* 
N= 1147 N= 1031 N= 116  
Male, n (%) 852/1133 (75.2) 759/1017 (74.6) 93 (80.2) 0.21 
Age (year), median (IQR) 40 (33-48) 40 (33-48) 40 (31- 49) 0.98 
Italian, n (%) 840/1053 (79.8) 768/966 (79.5) 72/87 (82.8) 0.57 
Risk factor, n (%):    <0.001 
Heterosexual 379 (33) 350 (33.9) 29 (25)  
Homo/bisexual 227 (19.8) 210 (20.4) 17 (14.7)  
Injection drug users 88 (7.7) 81 (7.9) 7 (6)  
Other/Unknown 453 (39.5) 390 (37.8) 63 (54.3)  
Geographical Area, n (%):    <0.001 
Northern Italy 478 (41.7) 446 (43.3) 32 (27.6)  
Central Italy 445 (38.8) 402 (39) 43 (37.1)  
Southern Italy and Islands 224 (19.5) 183 (17.7) 41 (35.3)  
Time from HIV diagnosis (YY), median (IQR) 0.3 (0.1-2.4) 0.2 (0.1-2.4) 0.4 (0.1-2.7) 0.38 
Baseline plasma HIV-1 RNA (log10 copies/mL), median 
(IQR) 4.9 (4.3-5.4) 5 (4.4-5.4) 4.6 (4-5.3) 0.002 
Baseline CD4 cell count (cells/mm3), median (IQR) 250 (99.8-378.3) 235 (94-362) 388 (206-554) <0.001 
CD4 nadir cell count (cells/mm3), median (IQR) 226 (94-342) 216 (89-332) 328 (167-496) <0.001 
Subtype, n (%):     
B 790 (68.9) 712 (69.1) 78 (67.2) 0.67 
non B 357 (31.1) 319 (30.9) 38 (32.8)  
Patients with transmitted drug resistance, n (%):     
NRTI 54 (4.7) 47 (4.6) 7 (6) 0.48 
NNRTI 51 (4.4) 48 (4.7) 3 (2.6) 0.47 
PI 17 (1.5) 14 (1.4) 3 (2.6) 0.24 
INSTI 0 0 0  
Backbone, n (%):     
TDF/FTC 858 (74.8) 773 (75) 85 (73.3) 0.73 
ABC/3TC 192 (16.7) 163 (15.8) 29 (25) 0.02 
AZT/3TC 87 (7.6) 87 (8.4) 0 (0) <0.001 
others 10 (0.9) 8 (0.8) 2 (1.7) 0.26 
Third drug     
DRV/r  287 (27.8)   
LPV/r  435 (42.2)   
ATV/r  309 (30)   
RAL   50 (43.1)  
EVG   28 (24.1)  
DTG   38 (32.8)  
